Naquet Philippe

Prof. Naquet Philippe


Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2020 in Progress in Lipid Research
Verified
Journal Article
Closed access
NPNaquet Philippe
Naquet Philippe
EKEvan W. Kerr
Evan W. Kerr
SVSchuyler D. Vickers
Schuyler D. Vickers
RLRoberta Leonardi
Roberta Leonardi

28 July 2023 in European Journal of Immunology
Verified
Journal Article
Open access
RMRichard Miallot
Richard Miallot
VMVirginie Millet
Virginie Millet
FGFranck Galland
Franck Galland
NPNaquet Philippe
Naquet Philippe
Coenzyme A (CoA) serves as a vital cofactor in numerous enzymatic reactions involved in energy production, lipid metabolism, and synthesis of essential molecules. Dysregulation of CoA‐dependent metabolic pathways can contribute to chronic diseases, such as inflammatory diseases, obesity, diabetes, cancer, and cardiovascular disorders. Additionally, CoA influences immune cell activation by modulating the metabolism of these cells, thereby affecting their proliferation, differentiation, and effector functions. Targeting CoA metabolism presents a promising avenue for therapeutic intervention, as it can potentially restore metabolic balance, mitigate chronic inflammation, and enhance immune cell function. This might ultimately improve the management and outcomes for these diseases. This review will more specifically focus on the contribution of pathways regulating the availability of the CoA precursor Vitamin B5/pantothenate in vivo and modulating the development of Th17‐mediated inflammation, CD8‐dependent anti‐tumor immunity but also tissue repair processes in chronic inflammatory or degenerative diseases.

1 June 1997 in European Journal of Immunology
Verified
Journal Article
Closed access
PDF file
MNMarianne Naspetti
Marianne Naspetti
MAMichel Aurrand-Lions
Michel Aurrand-Lions
JDJenefer Dekoning
Jenefer Dekoning
MMMarie Malissen
Marie Malissen
FGFranck Galland
Franck Galland
NPNaquet Philippe
Naquet Philippe

10 July 2018 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
CGCaroline Giessner
Caroline Giessner
VMVirginie Millet
Virginie Millet
KMKonrad J Mostert
Konrad J Mostert
TGThomas Gensollen
Thomas Gensollen
TMThien-Phong Vu Manh
Thien-Phong Vu Manh
NPNaquet Philippe
Naquet Philippe
Like other tumors, aggressive soft tissue sarcomas (STS) use glycolysis rather than mitochondrial oxidative phosphorylation (OXPHOS) for growth. Given the importance of the cofactor coenzyme A (CoA) in energy metabolism, we investigated the impact of Vnn1 pantetheinase—an enzyme that degrades pantetheine into pantothenate (vitamin B5, the CoA biosynthetic precursor) and cysyteamine—on tumor growth. Using two models, we show that Vnn1+STS remain differentiated and grow slowly, and that in patients a detectable level of VNN1 expression in STS is associated with an improved prognosis. Increasing pantetheinase activity in aggressive tumors limits their growth. Using combined approaches, we demonstrate that Vnn1 permits restoration of CoA pools, thereby maintaining OXPHOS. The simultaneous production of cysteamine limits glycolysis and release of lactate, resulting in a partial inhibition of STS growth in vitro and in vivo. We propose that the Warburg effect observed in aggressive STS is reversed by induction of Vnn1 pantetheinase and the rewiring of cellular energy metabolism by its products.

18 September 2001 in Histochemistry and Cell Biology
Verified
Journal Article
Closed access
PDF file
JGJean-Claude Guillemot
Jean-Claude Guillemot
MNMarianne Naspetti
Marianne Naspetti
FMFabrice Malergue
Fabrice Malergue
PMPhilippe Montcourrier
Philippe Montcourrier
FGFranck Galland
Franck Galland
NPNaquet Philippe
Naquet Philippe

1 February 2016 in Current Opinion in Immunology
Verified
Journal Article
Closed access
NPNaquet Philippe
Naquet Philippe
CGCaroline Giessner
Caroline Giessner
FGFranck Galland
Franck Galland